Presidential Executive Order Validates DeFloria's Strategy in Pharmaceutical Cannabinoid Drug Development

Executive Summary

• The U.S. Presidential Executive Order reclassifying cannabis from Schedule I to Schedule III validates DeFloria’s cannabinoid drug development strategy and is expected to unlock new research funding, partnership opportunities, and capital market interest.
• DeFloria received FDA clearance to proceed with a Phase 2 clinical trial of its oral solution AJA001 for irritability associated with autism spectrum disorder (ASD), building on a cleared IND, “Study May Proceed” letter, and completed Phase 1 PK/PD safety study.
• Company leadership highlights that the regulatory shift positions DeFloria as a partnership‑ready platform for pharmaceutical collaborators seeking cannabinoid‑based therapeutics.

Key Details

• Regulatory Milestone: FDA issued a “Study May Proceed” letter for IND AJA001, allowing initiation of Phase 2 trials targeting ASD‑related irritability.
• Phase 1 Results: Completed PK/PD study demonstrated safety and well‑tolerated dosing profile; data support progression to Phase 2.
• Executive Order Impact: Federal reclassification to Schedule III is projected to:
• Expand federal research funding for cannabinoid studies.
• Reduce regulatory barriers, facilitating academic collaborations and clinical trial enrollment.
• Lower compliance risk, encouraging institutional investment and pharma partnerships.
• Strategic Positioning: DeFloria’s standardized full‑spectrum hemp genetics, FDA‑compliant manufacturing, and robust safety data make it “partnership‑ready” for biopharma companies interested in cannabinoid therapeutics.
• Leadership Statements:
• Joel Stanley (Co‑Founder of Charlotte’s Web, Board Chair) emphasized the historic validation of cannabinoids by federal policy.
• Jared Stanley (CEO, DeFloria) noted that the timing aligns with capital inflows and strategic interest from pharmaceutical partners.

Notable Quotes

• “Federal policy is finally catching up to what patients, academics, and clinicians have long understood: cannabinoids hold real therapeutic power.” – Joel Stanley
• “This policy shift opens the door to an entirely new level of potential investment, partnership, and scientific collaboration.” – Jared Stanley